Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-Gastric 02
2024-519787-40-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing sonesitatug vedotin + capecitabine, sonesitatug vedotin + capecitabine + rilvegostomig and active comparator / standard-of-care control (3 arms). Primary endpoints: Progression Free Survival and Overall Survival. Planned start Jul 2026; status: authorised.
02
Drugs
sonesitatug vedotincapecitabinerilvegostomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2024-519787-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519787-40-00.